Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00071812 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)
A Phase 2 study, sponsored by Human Genome Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 283
- Enrollment target
NCT00071812 is a Phase 2 study that has completed, run by Human Genome Sciences. The registered enrollment target is 283 participants.
The verdict
NCT00071812, a Phase 2 study, has completed, sponsored by Human Genome Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 283 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of 3 different doses of belimumab, administered in addition to standard therapy, in patients with rheumatoid arthritis (RA).
Interventions
- DRUG Placebo
- DRUG Belimumab 1 mg/kg
- DRUG Belimumab 10 mg/kg
- DRUG Belimumab 4 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 283 participants |
| Start Date | 2003-12 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00071812
The ClinicalTrials.gov registry entry for NCT00071812 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 283 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Human Genome Sciences, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00071812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00071812 about?
NCT00071812 is a clinical study titled "A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)". The purpose of this study is to evaluate the safety and efficacy of 3 different doses of belimumab, administered in addition to standard therapy, in patients with rheumatoid arthritis (RA).
What is the current status of trial NCT00071812?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 283 participants. The study started on 2003-12. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00071812?
The interventions under investigation include: Placebo (DRUG), Belimumab 1 mg/kg (DRUG), Belimumab 10 mg/kg (DRUG), Belimumab 4 mg/kg (DRUG).
Who is sponsoring clinical trial NCT00071812?
This trial is sponsored by Human Genome Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.